Beximco Pharmaceuticals Limited

BXP.L · LSE
Analyze with AI
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Operating Activities
Net Income£5,867£4,524£5,123£5,128
Dep. & Amort.£1,994£2,061£370£1,114
Deferred Tax£0£0£0£0
Stock-Based Comp.£0£0£0£0
Change in WC£433-£734-£1,909-£653
Other Non-Cash£71£234£1,630£434
Operating Cash Flow£8,364£6,085£5,493£6,023
Investing Activities
PP&E Inv.-£1,994-£2,411-£2,939-£2,558
Net Acquisitions£0£0-£4,767£0
Inv. Purchases£0£0£0£0
Inv. Sales/Matur.£0£0£0£0
Other Inv. Act.-£413-£206£26£34
Investing Cash Flow-£2,406-£2,617-£7,680-£2,525
Financing Activities
Debt Repay.-£4,674-£1,993£4,238-£505
Stock Issued£0£0£0£0
Stock Repurch.£0£0£0£0
Dividends Paid-£1,586-£1,568-£1,623-£578
Other Fin. Act.£0£0£0-£2,375
Financing Cash Flow-£6,260-£3,561£2,615-£3,458
Forex Effect£20£60£45£0
Net Chg. in Cash-£282-£33£195£40
Supplemental Information
Beg. Cash£1,136£1,169£974£635
End Cash£854£1,136£1,169£675
Free Cash Flow£6,130£3,375£2,554£3,465